Plug and Play Upstream
Introducing our Plug & Play Upstream Development Service for Small-sized Biotechs
Adaptive solutions that help you get from DNA to clinic, the right way for you
You Need to Reach Preclinical Phase? What Now?
Article appeared in Labiotech.eu
Read our article
and find out what are the critical steps for small-sized biotechs to get through the
preclinical phase quickly and cost-effectively.
Merck Introduces New Integrated Plug & Play Upstream Development Service
Read our press release
Our innovative, custom approach
helps small biotechs accelerate their upstream development: Here’s how we do it
Case Study: Accelerate the Time from DNA to Material.
Based on our automated mini-pool approach
Learn how this approach allows to efficiently create, screen and isolate high producing clones with reduced cost and time. Other approaches will be described in this case study, such as cell type selection, expression cassette design and super-transfection.
Fast Track: Accelerate Identification of High-Producing Cell Lines
Based on a multiparallel workflow process
Learn from BDS Team Leader, Cyrielle Corbin, Ph.D. about our mini-pool approach as fast-track process and how we can begin process development in parallel with cell line development, reducing timelines by 10-13 weeks.
Our innovative, custom approach
helps small biotechs find nimble solutions for their upstream development: Here’s how we do it
Case Study: Increase the Titer of a Difficult to Express molecule
Based on a super-transfection approach
A customer sought to increase the titer of a molecule that had proven difficult to
express, with a titer insufficient for clinical studies. Learn how our strategy allowed to increase the titer nearly 4-fold after
generation of stable pools.
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell Line
Based on a 200 Liter scale
Learn how our customers reduce cost and time by leveraging our CHOZN® cell line and semi-automated approach to mini-pools and reach a 200L scale.
A service designed around your
needs - choose the path that’s right for you
Choose our proprietary CHOZN® platform, which allows for faster, simpler selection and scale-up of
Right First Time
We help you find the right balance between speed and efficiency, so your clone demonstrates high quality
productivity early on to avoid delays in your clinical trials.
Leverage our innovative approach to mini-pools and confidently run process development and clone
parallel and save up to 10 weeks.
Run analytical development in parallel to your cell line development to get you progressing faster.
transfer between our teams is seamless.
One Tailored Suite of Upstream
A plug & play service offering,
exaclty tailored to small-sized biotechs, needing to balance cost, risk and speed to
clinic without sacrificing quality
- Full cell line development services from your molecule of interest to
Research Cell Bank of the
- Validated cell line development process based on mini-pool approach and
validated limit dilution
- Variants and signal peptides screening possible during early phases of
- Monoclonality reports and stability validation in compliance with
- Add-on services for Analytical method development and product
- Fast-Track process using the mini-pool as early material for process
development saving 10-13 weeks
on overall project
Ask our Experts
Why is it important to get cell line development right first time?
Learn from BDS Scientist Clémence Justine about
factors that must be considered when optimizing recombinant antibody expression.
Generating a high-producing cell line is challenging. How do you make sure to get it right first
time on a reduced timeline?
Learn from Research BDS Scientist Lucie
Grinders about our mini-pool approach and how we can begin process development in
parallel with cell line development.
One advantage of the mini-pool approach is efficiency. How can you further accelerate the process?
Learn from BDS Team Leader, Cyrielle Corbin, Ph.D. how we
steps in parallel for
customers who have a very challenging timeline.
What are the advantages of your custom binding assays and how do you do it?
Learn from Senior Scientist Helen Hsu, Ph.D. how, with our
custom binding assays, and supported with our comprehensive off-the-shelf Fc gamma receptor binding
assays, we optimize your mAb production.
We are an adaptable CDMO partner for start-ups and small biotechs needing to develop and commercialize
biologics. We do this by balancing speed, risk and cost through custom solutions, by leveraging our bioprocessing
technologies and process development expertise, and by allowing our clients to transfer their
process and knowledge to their end point at any step of their drug development. To learn more, please
BioReliance® End-to-End Solutions - Your CDMO Partner.